Study Reveals GES Variants Impact Resistance to Ceftazidime-Avibactam and Imipenem-Relebactam
Distinct GES variants influence resistance patterns to ceftazidime-avibactam and imipenem-relebactam in CRPA.
Therapeutic Area
Therapeutic area intelligence for Antibiotic Resistance with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.